CBT-I More Effective and Safer Than Sleep Meds for Chronic Insomnia

Cognitive-behavioral therapy offers a safer and more effective alternative to sleep medications for chronic insomnia and is now accessible through self-guided applications, according to a presentation delivered at the Family Medicine Forum 2026.

Healthcare providers should actively work to wean patients from sleep medications such as sedatives when those drugs are no longer clinically necessary, David Gardner, PharmD, professor of psychiatry at Dalhousie University in Halifax, told Medscape News Canada. “Now is the time for us to be all together on this, to be a part of the transformation of insomnia management from pharmacologic to nonpharmacologic approaches,” Gardner said.

While basic sleep hygiene recommendations—such as limiting electronic device usage before bedtime and keeping the sleeping environment dark—can alleviate short-term sleep disturbances, they typically fail to resolve chronic conditions.

Chronic insomnia involves persistent difficulty initiating or maintaining sleep occurring on at least three nights per week for a duration of three months or longer. Establishing consistent bedtimes and rise times along with restricting bedroom activities strictly to sleep, illness, and sex can assist in managing severe symptoms.

However, cognitive-behavioral therapy for insomnia, known as CBT-I, serves as a structured four- to eight-week program that combines cognitive reframing with behavioral strategies. Patients learn to modify detrimental habits and alter underlying thought patterns that prevent restful sleep.

Plain English Sleep Interventions

  • Targeted Behavioral Shifts: CBT-I helps patients address specific cognitive barriers and behavioral routines that perpetuate ongoing sleep disruptions.
  • Reduced Reliance on Sedatives: Transitioning away from pharmaceutical agents minimizes long-term risks such as cognitive impairment and accidental falls.
  • Digital Accessibility: Self-guided mobile applications and structured programs like Sleepwell make evidence-based techniques available outside of traditional clinical settings.

Although CBT-I was once restricted to specialized in-person therapy sessions, self-guided formats have expanded availability. Gardner recommends that clinicians and patients utilize the nonprofit Sleepwell platform as a centralized resource for discovering approved apps and guided programs. The primary objective of Sleepwell is to help individuals improve sleep quality while safely discontinuing sleeping pills.

Finding nonpharmacological alternatives is particularly critical because prescription sleep aid usage increases steadily among older adults, peaking in their eighties and nineties. Gardner said that vulnerability to adverse drug reactions is highest within elderly and frail populations.

Documented risks associated with pharmaceutical sedatives include accidental falls, bone fractures, cognitive decline, and increased susceptibility to flu-related pneumonia driven by drug-induced immune suppression. These pharmacological agents fail to treat the root causes driving chronic sleep pathologies.

Sedative Efficacy and Clinical Risks

Researchers have evaluated the efficacy of the benzodiazepine medication temazepam against a placebo control group. With the active drug, the time required to initiate sleep was 11 minutes shorter when measured via polysomnography and 7 minutes shorter based on patient self-assessment, while total sleep time increased by 21 minutes. To mitigate reliance on these substances, clinicians can avoid initial prescriptions, prevent dose escalations, and initiate formal deprescribing protocols.

Deprescribing involves structured dialogues addressing why patients take sedatives, how effective they perceive them to be, and whether they experience associated adverse events, Stephanie Lynch, PharmD, a pharmacist and research lead at Queen’s University in Belleville-Quinte, Ontario, told Medscape News Canada. Utilizing a sleep diary helps document exact sleep timing, overnight awakenings, daytime naps, and the concurrent consumption of alcohol, cannabis, and sleep medications.

CBT-I should serve as the default therapeutic option for patients suffering from severe insomnia, Guylène Thériault, MD, a family physician practicing in Gatineau, Quebec, told Medscape News Canada. Clinical data demonstrates that the number needed to treat using CBT-I is three. “I have to offer CBT-I to three patients for one of them to have success, which is huge and better than a pharmaceutical treatment,” Thériault said.

Thériault, who has spent three decades in medical practice, said that CBT-I was not part of her formal medical school curriculum, though she welcomes the growing array of patient resources. Alongside Sleepwell, clinicians can access patient education materials and deprescribing schedules through the Canadian Medication Appropriateness and Deprescribing Network and Choosing Wisely Canada. Transitioning patients away from long-term benzodiazepines remains challenging, but clinical discussions must address these modifications.

Contraindications and When to Consult a Doctor

Funding for the Sleepwell initiative is provided by the Drug Evaluation Alliance of Nova Scotia and the government of Nova Scotia. Gardner and Lynch reported no relevant financial relationships, while Thériault reported receiving an honorarium from Choosing Wisely Canada.

References

  • Family Medicine Forum (FMF) 2026 Proceedings. Medscape News Canada.
  • Choosing Wisely Canada. Deprescribing Sedative-Hypnotics Guidelines.
  • Canadian Medication Appropriateness and Deprescribing Network. Clinical Tools.
Photo of author

Health Desk

Health Desk at Archyde.

Yankees’ Cashman: Clubs Inquiring on Domínguez Amid Winter Performance

Researchers Detail Automated Dish System for Assisted Reproductive Technology